Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 28 Apr 2026 | Jana Dabbelt Cabinet member | EUCOPE - Strasbourg | SRC |
| 28 Apr 2026 | Jana Dabbelt Cabinet member | EUCOPE - Strasbourg | — |
Mission & Goals
Sobi is a global biopharmaceutical company specialized in rare diseases developing and providing access to innovative treatments in the areas of haematology, immunology and specialty care. Sobi offers an integrated process, from in-house research and development in protein characterisation, biologics manufacturing and industrialisation, to commercialisation of products for rare diseases. Partnering with stakeholders and facilitating effective and timely rare-disease therapy development, including an extensive and robust distribution network, creates unique opportunities for us to add value to the rare-disease field.
EU Legislative Interests
Rare Disease Action Plan Joint Procurement General Pharmaceutical Legislation Pharmaceutical IP EU HTA Security of supply EU Biotech Act Safe Hearts Plan
Communication Activities
- European Commission Regulation on health technology assessment and amending Directive 2011/24/EU - European Commission study on the evaluation of the EU Orphan & Paediatric legislation - European Commission Pharmaceutical Strategy - European Parliament/EU Commission EU4Health Programme (particularly for rare diseases, ERNs)
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Sobi is member of EUCOPE https://www.eucope.org/members/ Sobi is a member of the European Business Summits https://ebsummits.eu/
Organisation Members
https://www.sobi.com/en/trade-association-memberships